Company Website:
http://zlk.9nl.com/zalicus-zlcs
NEW YORK -- (Business Wire)
Levi & Korsinsky is investigating the Board of Directors of Zalicus,
Inc. (“Zalicus” or “the Company”) (NasdaqCM:ZLCS) for possible breaches
of fiduciary duty and other violations of state law in connection with
the sale of the Company to Epirus Biopharmaceuticals.
Click here to learn more about the action http://zlk.9nl.com/zalicus-zlcs,
or call: 877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Zalicus shareholders will own a
percentage of the post-merger company; this percentage is subject to an
adjustment at closing based on the level of Zalicus net cash. Based on
Zalicus’ net cash as of April 16, 2014, the day the merger was
announced, Zalicus shareholders would own just 14% of the combined
company. The investigation concerns whether the Zalicus Board of
directors breached their fiduciary duties to stockholders by failing to
adequately shop the Company before agreeing to enter into this
transaction, and whether Epirus Biopharmaceuticals is underpaying for
Zalicus shares.
If you own Zalicus common stock and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/zalicus-zlcs.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Contacts:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky,
Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax:
866-367-6510
www.zlk.com
Source: Levi & Korsinsky, LLP
© 2024 Canjex Publishing Ltd. All rights reserved.